🎉 M&A multiples are live!
Check it out!

Coherus BioSciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Coherus BioSciences and other public comps.

See Coherus BioSciences Valuation Multiples

Coherus BioSciences Overview

About Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.


Founded

2010

HQ

United States of America
Employees

306

Website

coherus.com

Financials

LTM Revenue $252M

LTM EBITDA -$84.3M

EV

$302M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Coherus BioSciences Financials

Coherus BioSciences has a last 12-month revenue of $252M and a last 12-month EBITDA of -$84.3M.

In the most recent fiscal year, Coherus BioSciences achieved revenue of $257M and an EBITDA of -$194M.

Coherus BioSciences expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Coherus BioSciences valuation multiples based on analyst estimates

Coherus BioSciences P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue $211M $257M $256M $252M XXX
Gross Profit $269M $141M $98.3M XXX XXX
Gross Margin 127% 55% 38% XXX XXX
EBITDA -$256M -$194M -$85.9M -$84.3M XXX
EBITDA Margin -121% -75% -34% -33% XXX
Net Profit -$287M -$292M -$238M XXX XXX
Net Margin -136% -113% -93% XXX XXX
Net Debt n/a $408M $370M XXX XXX

Financial data powered by Morningstar, Inc.

Coherus BioSciences Stock Performance

As of February 7, 2025, Coherus BioSciences's stock price is $1.

Coherus BioSciences has current market cap of $130M, and EV of $302M.

See Coherus BioSciences trading valuation data

Coherus BioSciences Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$302M $130M XXX XXX XXX XXX $0.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Coherus BioSciences Valuation Multiples

As of February 7, 2025, Coherus BioSciences has market cap of $130M and EV of $302M.

Coherus BioSciences's trades at 1.2x LTM EV/Revenue multiple, and -3.6x LTM EBITDA.

Analysts estimate Coherus BioSciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Coherus BioSciences and 10K+ public comps

Coherus BioSciences Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $302M XXX XXX XXX
EV/Revenue 1.2x XXX XXX XXX
EV/EBITDA -3.5x XXX XXX XXX
P/E 3.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -4.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Coherus BioSciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Coherus BioSciences Valuation Multiples

Coherus BioSciences's NTM/LTM revenue growth is -12%

Coherus BioSciences's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Coherus BioSciences's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Coherus BioSciences's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Coherus BioSciences and other 10K+ public comps

Coherus BioSciences Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 0% XXX XXX XXX XXX
EBITDA Margin -34% XXX XXX XXX XXX
EBITDA Growth -56% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -45% XXX XXX XXX XXX
Revenue per Employee $0.8M XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 43% XXX XXX XXX XXX
Opex to Revenue 117% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Coherus BioSciences Public Comps

See valuation multiples for Coherus BioSciences public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Coherus BioSciences M&A and Investment Activity

Coherus BioSciences acquired  XXX companies to date.

Last acquisition by Coherus BioSciences was  XXXXXXXX, XXXXX XXXXX XXXXXX . Coherus BioSciences acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Coherus BioSciences

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Coherus BioSciences

When was Coherus BioSciences founded? Coherus BioSciences was founded in 2010.
Where is Coherus BioSciences headquartered? Coherus BioSciences is headquartered in United States of America.
How many employees does Coherus BioSciences have? As of today, Coherus BioSciences has 306 employees.
Who is the CEO of Coherus BioSciences? Coherus BioSciences's CEO is Mr. Dennis M. Lanfear.
Is Coherus BioSciences publicy listed? Yes, Coherus BioSciences is a public company listed on NAS.
What is the stock symbol of Coherus BioSciences? Coherus BioSciences trades under CHRS ticker.
When did Coherus BioSciences go public? Coherus BioSciences went public in 2014.
Who are competitors of Coherus BioSciences? Similar companies to Coherus BioSciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Coherus BioSciences? Coherus BioSciences's current market cap is $130M
What is the current revenue of Coherus BioSciences? Coherus BioSciences's last 12-month revenue is $252M.
What is the current EBITDA of Coherus BioSciences? Coherus BioSciences's last 12-month EBITDA is -$84.3M.
What is the current EV/Revenue multiple of Coherus BioSciences? Current revenue multiple of Coherus BioSciences is 1.2x.
What is the current EV/EBITDA multiple of Coherus BioSciences? Current EBITDA multiple of Coherus BioSciences is -3.6x.
What is the current revenue growth of Coherus BioSciences? Coherus BioSciences revenue growth between 2023 and 2024 was 0%.
Is Coherus BioSciences profitable? Yes, Coherus BioSciences is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.